Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Press release

Alligator Bioscience: BioStock: Alligator meets primary endpoint with CD40 agonist in pancreatic cancer

Alligator Bioscience

Alligator Bioscience has released positive top-line data from the phase II trial assessing the efficacy of the CD40 agonist mitazalimab in pancreatic cancer. Having met the primary endpoint, the company can now start preparing for phase III. Alligator's CEO Søren Bregenholt stopped by the BioStock studio in Lund to give us a rundown of the results.

Watch the interview with Alligator Bioscience's CEO Søren Bregenholt at biostock.se:

Alligator meets primary endpoint with CD40 agonist in pancreatic cancer - BioStock (https://www.biostock.se/en/2024/01/alligator-meets-primary-endpoint-with-cd40-agonist-in-pancreatic-cancer/)
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.